TNG908

• CAT Number: I042003
• CAS Number: 2760481-53-4
• Purity: ≥95%
• Synonyms: N-(6-amino-5-methylpyridin-3-yl)-2-[(2R,5S)-2-(1,3-benzothiazol-5-yl)-5-methylpiperidin-1-yl]-2-oxoacetamide
• InChI: InChI=1S/C21H23N5O2S/c1-12-3-5-17(14-4-6-18-16(8-14)24-11-29-18)26(10-12)21(28)20(27)25-15-7-13(2)19(22)23-9-15/h4,6-9,11-12,17H,3,5,10H2,1-2H3,(H2,22,23)(H,25,27)/t12-,17+/m0/s1
• InChIKey: NXXBDYHMHHINFC-YVEFUNNKSA-N
• SMILES: CC1CCC(N(C1)C(=O)C(=O)NC2=CN=C(C(=C2)C)N)C3=CC4=C(C=C3)SC=N4

TNG908 is a MTAP synergistic PRMT5 inhibitor. TNG908 crosses the blood-brain barrier and is orally active. TNG908 could be used in cancer research[1].
TNG908 (0-10 μM, 24 h) is 15 times more selective for MTAPnull cell lines than MTAPWT cell lines, and the stability of human liver microsomes is C< sub>lint=14 μL/min/mg[1].
TNG908 (1-120 mg/kg twice daily for 21 days, p.o. or i.v.) A promotes tumor regression in LU99 NSCLC cell line-derived xenograft mouse model[1].
Pharmacokinetic Analysis in SD Rats[1]

Route
Dose (mg/kg)
clearance (mL/min/kg)
Vss_obs (L/kg)
T1/2 (h)
Cmax (μg/mL)
AUCINF (μg·h/mL)

p.o.
1
38.2
1.5
2
/
/

p.o.
3
/
/
/
0.6
2.5